New Guidelines Set for Psychedelic-Assisted Therapy: A Milestone in Mental Health Treatment
The American Psychedelic Practitioners Association (APPA) and BrainFutures have released the first professional practice guidelines for psychedelic-assisted therapy. Developed by a multidisciplinary working group, these guidelines aim to establish benchmarks for the safe integration of psychedelics into the US healthcare system, focusing on best practices, ethics, safety, and the inclusion of diverse perspectives.
- Guidelines were developed by field leaders, including more than 24 APPA members.
- Topics covered include justice, equity, diversity, inclusion, best practices, and use in various settings.
- Focus on preparation, informed consent, trust-building, and post-medication integration.
- Guidelines will expire in two years, with updates to follow as more research becomes available.
- Anticipation of MDMA approval for PTSD treatment next year and other therapies in the pipeline.
- Andrew Penn, a key working group member, emphasized the importance of these guidelines in professionalizing psychedelic therapy.
- The guidelines also address coordination with other providers and patient safety.
- The guidelines mark a significant step in the evolution of psychedelic therapy, aiming to protect patients and promote the safe use of psychedelic medicines in professional settings.